Quantitative measure of golimumab.

Promonitor®-GLM is an enzyme-linked immunosorbent assay (ELISA) for the quantitative detection of golimumab (GLM) in human serum. It is used as an aid in monitoring patient´s clinical response to GLM therapy in conjunction with other clinical findings. The amount of GLM, anti-GLM antibodies (Promonitor®-ANTI-GLM Ref. 5210230000) and clinical findings, like disease activity, can contribute valuable information to the physician to make a more accurate evaluation of the response to the treatment with GLM.

Promonitor®-GLM is a capture ELISA. The microwell strips are provided pre-coated with an anti-TNFa human monoclonal antibody bound to recombinant human TNFa. Pre-diluted Calibrators, Controls and diluted patient samples are added to separate wells, allowing GLM present to bind to pre-immobilized Anti-GLM antibodies. Unbound sample is washed away, and a second HRP-labeled anti-GLM monoclonal antibody is added to each well. A second incubation step allows the HRP-labeled anti-GLM antibody to bind to the GLM that has become attached to the microwells. After washing away the excess of unbound HRP-labeled anti-GLM antibody, the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops in a spectrophotometer. The signal obtained is proportional to the amount of drug in the patient sample.

Optical densities (OD) of the calibrators are plotted to construct the GLM calibration curve. A four parameter logistic (4PL) model is used to fit the curve. Positive and Negative Controls are used to monitor assay performance. GLM concentration is calculated by interpolating sample OD in the calibration curve. Warnings for each sample are optionally included; this setting can be configured here.

See also

Related: Promonitor®-anti-GLM Ref. 521XX30000